Cargando…

Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant

The newly emerged BA.2.75 SARS-CoV-2 variant exhibits an alarming 9 additional mutations in its spike (S) protein compared to the ancestral BA.2 variant. Here we examine the neutralizing antibody escape of BA.2.75 in mRNA-vaccinated and BA.1-infected individuals, as well as the molecular basis under...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Panke, Evans, John P., Zheng, Yi-Min, Carlin, Claire, Saif, Linda J., Oltz, Eugene M., Xu, Kai, Gumina, Richard J., Liu, Shan-Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413709/
https://www.ncbi.nlm.nih.gov/pubmed/36032970
http://dx.doi.org/10.1101/2022.08.14.503921
_version_ 1784775816557625344
author Qu, Panke
Evans, John P.
Zheng, Yi-Min
Carlin, Claire
Saif, Linda J.
Oltz, Eugene M.
Xu, Kai
Gumina, Richard J.
Liu, Shan-Lu
author_facet Qu, Panke
Evans, John P.
Zheng, Yi-Min
Carlin, Claire
Saif, Linda J.
Oltz, Eugene M.
Xu, Kai
Gumina, Richard J.
Liu, Shan-Lu
author_sort Qu, Panke
collection PubMed
description The newly emerged BA.2.75 SARS-CoV-2 variant exhibits an alarming 9 additional mutations in its spike (S) protein compared to the ancestral BA.2 variant. Here we examine the neutralizing antibody escape of BA.2.75 in mRNA-vaccinated and BA.1-infected individuals, as well as the molecular basis underlying functional changes in the S protein. Notably, BA.2.75 exhibits enhanced neutralization resistance over BA.2, but less than the BA.4/5 variant. The G446S and N460K mutations of BA.2.75 are primarily responsible for its enhanced resistance to neutralizing antibodies. The R493Q mutation, a reversion to the prototype sequence, reduces BA.2.75 neutralization resistance. The mutational impact is consistent with their locations in common neutralizing antibody epitopes. Further, the BA.2.75 variant shows enhanced cell-cell fusion over BA.2, driven largely by the N460K mutation, which enhances S processing. Structural modeling revealed a new receptor contact introduced by N460K, supporting a mechanism of potentiated receptor utilization and syncytia formation.
format Online
Article
Text
id pubmed-9413709
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-94137092022-08-27 Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant Qu, Panke Evans, John P. Zheng, Yi-Min Carlin, Claire Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu bioRxiv Article The newly emerged BA.2.75 SARS-CoV-2 variant exhibits an alarming 9 additional mutations in its spike (S) protein compared to the ancestral BA.2 variant. Here we examine the neutralizing antibody escape of BA.2.75 in mRNA-vaccinated and BA.1-infected individuals, as well as the molecular basis underlying functional changes in the S protein. Notably, BA.2.75 exhibits enhanced neutralization resistance over BA.2, but less than the BA.4/5 variant. The G446S and N460K mutations of BA.2.75 are primarily responsible for its enhanced resistance to neutralizing antibodies. The R493Q mutation, a reversion to the prototype sequence, reduces BA.2.75 neutralization resistance. The mutational impact is consistent with their locations in common neutralizing antibody epitopes. Further, the BA.2.75 variant shows enhanced cell-cell fusion over BA.2, driven largely by the N460K mutation, which enhances S processing. Structural modeling revealed a new receptor contact introduced by N460K, supporting a mechanism of potentiated receptor utilization and syncytia formation. Cold Spring Harbor Laboratory 2022-08-15 /pmc/articles/PMC9413709/ /pubmed/36032970 http://dx.doi.org/10.1101/2022.08.14.503921 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Qu, Panke
Evans, John P.
Zheng, Yi-Min
Carlin, Claire
Saif, Linda J.
Oltz, Eugene M.
Xu, Kai
Gumina, Richard J.
Liu, Shan-Lu
Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
title Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
title_full Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
title_fullStr Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
title_full_unstemmed Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
title_short Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
title_sort evasion of neutralizing antibody response by the sars-cov-2 ba.2.75 variant
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413709/
https://www.ncbi.nlm.nih.gov/pubmed/36032970
http://dx.doi.org/10.1101/2022.08.14.503921
work_keys_str_mv AT qupanke evasionofneutralizingantibodyresponsebythesarscov2ba275variant
AT evansjohnp evasionofneutralizingantibodyresponsebythesarscov2ba275variant
AT zhengyimin evasionofneutralizingantibodyresponsebythesarscov2ba275variant
AT carlinclaire evasionofneutralizingantibodyresponsebythesarscov2ba275variant
AT saiflindaj evasionofneutralizingantibodyresponsebythesarscov2ba275variant
AT oltzeugenem evasionofneutralizingantibodyresponsebythesarscov2ba275variant
AT xukai evasionofneutralizingantibodyresponsebythesarscov2ba275variant
AT guminarichardj evasionofneutralizingantibodyresponsebythesarscov2ba275variant
AT liushanlu evasionofneutralizingantibodyresponsebythesarscov2ba275variant